{"id":"https://openalex.org/W125680830","doi":null,"title":"[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].","display_name":"[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].","publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W125680830","mag":"125680830","pmid":"https://pubmed.ncbi.nlm.nih.gov/21649590"},"language":"ru","primary_location":{"id":"pmid:21649590","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21649590","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Kardiologiia","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050387718","display_name":"Maya S. Safarova","orcid":"https://orcid.org/0000-0003-3069-3752","observed_orcids":["https://orcid.org/0000-0003-3069-3752"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M S Safarova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060925864","display_name":"\u0415 \u041f \u0422\u0440\u0443\u0445\u0430\u0447\u0435\u0432\u0430","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E P Trukhacheva","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069633649","display_name":"Ezhov Mv","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M V Ezhov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113984376","display_name":"\u041e \u0418 \u0410\u0444\u0430\u043d\u0430\u0441\u044c\u0435\u0432\u0430","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"O I Afanas'eva","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032211915","display_name":"M I Afanas'eva","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M I Afanas'eva","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075459096","display_name":"Maria I. Tripoten","orcid":"https://orcid.org/0000-0003-4462-3894","observed_orcids":["https://orcid.org/0000-0003-4462-3894"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M I Tripoten'","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023640194","display_name":"A A Liakishev","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A A Liakishev","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5017338642","display_name":"\u0421. \u041d. \u041f\u043e\u043a\u0440\u043e\u0432\u0441\u043a\u0438\u0439","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S N Pokrovski\u012d","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.6475,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.73047341,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"51","issue":"5","first_page":"9","last_page":"16"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/niacin","display_name":"nicotinic acid","score":0.9900000095367432},{"id":"https://openalex.org/keywords/coronary-artery-disease","display_name":"coronary artery disease","score":0.890999972820282},{"id":"https://openalex.org/keywords/lipoprotein-a","display_name":"lipoprotein(a)","score":0.9660000205039978},{"id":"https://openalex.org/keywords/atherosclerosis","display_name":"atherosclerosis","score":0.6779999732971191},{"id":"https://openalex.org/keywords/carotid-intima-media-thickness","display_name":"carotid intima-media thickness","score":0.9800000190734863},{"id":"https://openalex.org/keywords/atorvastatin","display_name":"atorvastatin","score":0.9679999947547913},{"id":"https://openalex.org/keywords/ldl-cholesterol","display_name":"LDL cholesterol","score":0.6079999804496765},{"id":"https://openalex.org/keywords/hdl-cholesterol","display_name":"HDL cholesterol","score":0.7639999985694885},{"id":"https://openalex.org/keywords/lipoprotein-associated-phospholipase-a2","display_name":"lipoprotein-associated phospholipase A2","score":0.9729999899864197},{"id":"https://openalex.org/keywords/c-reactive-protein","display_name":"C-reactive protein","score":0.8880000114440918},{"id":"https://openalex.org/keywords/lipid-profile","display_name":"lipid profile","score":0.5609999895095825},{"id":"https://openalex.org/keywords/men","display_name":"men","score":0.5979999899864197},{"id":"https://openalex.org/keywords/pleiotropy","display_name":"pleiotropy","score":0.7559999823570251}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8959240913391113},{"id":"https://openalex.org/C2777034527","wikidata":"https://www.wikidata.org/wiki/Q18032676","display_name":"Lipoprotein-associated phospholipase A2","level":4,"score":0.7753466367721558},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7637583017349243},{"id":"https://openalex.org/C2780092750","wikidata":"https://www.wikidata.org/wiki/Q134658","display_name":"Niacin","level":2,"score":0.7352654933929443},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.5384713411331177},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5345399379730225},{"id":"https://openalex.org/C2779679481","wikidata":"https://www.wikidata.org/wiki/Q13581432","display_name":"Plasminogen activator","level":2,"score":0.529399037361145},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.5033037066459656},{"id":"https://openalex.org/C2777482532","wikidata":"https://www.wikidata.org/wiki/Q668093","display_name":"Atorvastatin","level":2,"score":0.4957374036312103},{"id":"https://openalex.org/C2776104379","wikidata":"https://www.wikidata.org/wiki/Q21112670","display_name":"Lipoprotein(a)","level":4,"score":0.4809655249118805},{"id":"https://openalex.org/C2780675426","wikidata":"https://www.wikidata.org/wiki/Q410485","display_name":"Plasminogen activator inhibitor-1","level":3,"score":0.4396825134754181},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3680458664894104}],"mesh":[{"descriptor_ui":"D000069059","descriptor_name":"Atorvastatin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000960","descriptor_name":"Hypolipidemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002339","descriptor_name":"Carotid Arteries","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D002339","descriptor_name":"Carotid Arteries","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D003324","descriptor_name":"Coronary Artery Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003324","descriptor_name":"Coronary Artery Disease","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D003324","descriptor_name":"Coronary Artery Disease","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006538","descriptor_name":"Heptanoic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006538","descriptor_name":"Heptanoic Acids","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006951","descriptor_name":"Hyperlipoproteinemias","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006951","descriptor_name":"Hyperlipoproteinemias","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D006951","descriptor_name":"Hyperlipoproteinemias","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009525","descriptor_name":"Niacin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D009525","descriptor_name":"Niacin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017270","descriptor_name":"Lipoprotein(a)","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D017395","descriptor_name":"Plasminogen Activator Inhibitor 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D017539","descriptor_name":"Tunica Intima","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D017539","descriptor_name":"Tunica Intima","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D043203","descriptor_name":"1-Alkyl-2-acetylglycerophosphocholine Esterase","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D050197","descriptor_name":"Atherosclerosis","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D050197","descriptor_name":"Atherosclerosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D050197","descriptor_name":"Atherosclerosis","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D050197","descriptor_name":"Atherosclerosis","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D050356","descriptor_name":"Lipid Metabolism","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:21649590","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21649590","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Kardiologiia","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2945305106","https://openalex.org/W1971002603","https://openalex.org/W7097061542","https://openalex.org/W2169033201","https://openalex.org/W2063259781","https://openalex.org/W2104463342","https://openalex.org/W2011942596","https://openalex.org/W2049858854","https://openalex.org/W2439473611","https://openalex.org/W2411361656"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"assess":[2],"effects":[3],"of":[4,9,35,55,94,152,173,208,228,243,250,255,278,296,301,318],"niacin":[5],"on":[6,252,266,281,314],"risk":[7],"factors":[8],"atherosclerosis":[10],"in":[11,128,248,258,304],"men":[12,27,237],"with":[13,32,64,98,238,306],"coronary":[14],"heart":[15],"disease":[16],"(CHD)":[17],"and":[18,114,131,165,179,188,240,263,285],"high":[19,79,307],"lipoprotein(a)":[20],"[Lp(a)]":[21],"levels.":[22,144],"MATERIAL":[23],"AND":[24],"METHODS:":[25],"Sixty":[26],"(mean":[28],"age":[29],"54+/-6":[30],"years)":[31],"angiographic":[33],"evidence":[34,295],"CHD":[36,239],"were":[37,71,140,233],"randomized":[38],"into":[39],"two":[40],"groups.":[41],"Active":[42],"group":[43,53,148,225],"(n=30)":[44],"received":[45,61],"extended":[46],"release":[47],"nicotinic":[48,206,279],"acid":[49,200,207,280],"1500":[50],"mg,":[51],"control":[52,224],"consisted":[54],"remaining":[56],"30":[57],"patients.":[58],"All":[59],"patients":[60,305],"basic":[62],"therapy":[63],"atorvastatin":[65,246],"10-40":[66],"mg":[67],"qd.":[68],"Blood":[69],"samples":[70],"collected":[72],"for":[73,310],"total":[74],"cholesterol":[75,82],"(TC),":[76],"triglycerides":[77],"(TG),":[78],"density":[80],"lipoprotein":[81],"(HDL-C),":[83],"Lp(a),":[84,282],"lipoprotein-associated":[85],"phospholipase":[86],"A2":[87],"(Lp-PL-2),":[88],"high-sensitivity":[89],"C-reactive":[90],"protein":[91],"(hsCRP),":[92],"complex":[93,276],"tissue-type":[95],"plasminogen":[96,99],"activator":[97,100],"inhibitor":[101],"type":[102],"1":[103],"(tPA/PAI-1).":[104],"Carotid":[105],"intima":[106],"media":[107],"thickness":[108],"(CIMT)":[109],"was":[110,120,155],"measured":[111],"at":[112],"baseline":[113],"after":[115,162,170],"6-months":[116],"therapy.":[117],"RESULTS:":[118],"There":[119],"no":[121,226],"statistically":[122,203],"significant":[123,204,264],"difference":[124],"between":[125],"the":[126,129,135,142,146,209,267,275,290,294],"groups":[127],"clinical":[130],"biochemical":[132],"characteristics.":[133],"During":[134],"study":[136,292],"lipid":[137],"profile":[138],"data":[139],"within":[141],"target":[143],"In":[145,223,236],"active":[147],"median":[149],"percent":[150],"decrease":[151],"Lp(a)":[153,241,298,308],"level":[154],"23%":[156],"(from":[157],"84+/-40":[158],"to":[159,167,245,274],"67+/-25":[160],"mg/dl":[161,169],"6":[163,171,259],"weeks":[164],"up":[166],"65+/-37":[168],"months":[172],"treatment,":[174],"p<0.01);":[175],"LDL-C,":[176],"TG,":[177],"tPA/PAI-1,":[178],"Lp-PL-2":[180,284],"mass":[181],"levels":[182,309],"decreased":[183],"by":[184,193],"25,":[185,187],"20,":[186],"32%,":[189],"respectively;":[190],"HDL-C":[191],"increased":[192],"16%":[194],"(p<0.05":[195],"vs":[196,214,220],"baseline,":[197],"respectively).":[198],"Nicotinic":[199],"treatment":[201],"produced":[202],"reduction":[205],"mean":[210],"CIMT":[211,229,251],"(right:":[212],"0.83+/-0.16":[213],"0.77+/-0.17":[215],"mm,":[216],"p<0.05;":[217],"left:":[218],"0.88+/-0.21":[219],"0.82+/-0.17,":[221],"p<0.05).":[222],"changes":[227],"or":[230],"blood":[231],"tests":[232],"observed.":[234],"CONCLUSION:":[235],"excess":[242],"addition":[244],"results":[247],"regression":[249],"an":[253],"average":[254],"0.06":[256],"mm":[257],"months.":[260],"Such":[261],"rapid":[262],"effect":[265,313],"arterial":[268],"wall":[269],"structure":[270],"can":[271],"be":[272],"attributed":[273],"influence":[277],"lipids,":[283],"thrombogenic":[286],"factors.":[287],"This":[288],"is":[289],"first":[291],"providing":[293],"using":[297],"as":[299],"one":[300],"therapeutic":[302],"targets":[303],"achieving":[311],"beneficial":[312],"a":[315],"surrogate":[316],"marker":[317],"atherosclerosis.":[319]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2016-06-24T00:00:00"}